Table 1. Patient characteristics and technical parameters.
| Number (n), mean +/- SD or median with 25% and 75% percentile | |
|---|---|
| patients (n) | 30 (100%) |
| male / female (n) | 23 / 7 (77% / 23%) |
| age, years (mean +/- SD) | 60.2 +/- 14.99 |
| MGMT status (n = 27) | |
| methylated | 13 (48%) |
| unmethylated | 14 (52%) |
| IDH status (n = 21) | |
| wildtype (n) | 20 (95%) |
| mutation (n) | 1 (5%) |
| Chemotherapy | |
| Temozolomide (n) | 26 (87%) |
| Bevacizumab (n) | 2 (7%) |
| Radiotherapy | |
| received (n) | 30 (100%) |
| initial dose in Gy (n = 28) | 60 (60–60) |
| MRI scans (n) | |
| 3 | 6 |
| 4 | 3 |
| 5 | 7 |
| 6 | 7 |
| 7 | 4 |
| 8 | 1 |
| 10 | 1 |
| 12 | 1 |
| CV segmentations (n) | 165 |
| CV in ml (median) | 2.80 (0.30–10.90) |
| dCV in ml (median) | 0.00 (-2.60–3.40) |
| sCV in ml (median) | 1.49 (0.11–6.24) |
| FV segmentations (n) | 165 |
| FV in ml (median) | 50.10 (26.20–92.40) |
| dFV in ml (median) | 0.80 (-16.10–19.30) |
| sFV in ml (median) | 17.22 (7.48–35.18) |
| RC—MC categories | |
| 0 “initial diagnosis” (n) | 6 (3.6%)–6 (3.6%) |
| 1 “postoperative” (n) | 33 (20.0%)–33 (20.0%) |
| 2 “regression” (n) | 11 (6.7%)–11 (6.7%) |
| 3 “stable” (n) | 19 (11.5%)–17 (10.3%) |
| 4 “uncertain progression” (n) | 21 (12.7%)–15 (9.1%) |
| 5 “progression” (n) | 75 (45.5%)–83 (50.3%) |
SD = standard deviation, CV = contrast enhancing volume, dCV = absolute change of CV between two consecutive MRI time points, sCV = regional, segmentation-based subtractions of CV between two consecutive MRI time points, FV = FLAIR hyperintense volume, dFV = absolute change of FV between two consecutive MRI time points, sFV = regional, segmentation-based subtractions of FV between two consecutive MRI time points, RC = radiologic consensus, MC = multidisciplinary consensus.